Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Co-Exclusive License: Compositions and Methods Related to the Detection of Philadelphia Chromosome Translocations Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 11, 2001 will be considered.
View Development of SH2 Domain Antagonists Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential preliminary CRADA proposals, preferably two pages or less, must be submitted to the NCI on or before May 9, 2001. Guidelines for preparing final CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest.
View Prospective Grant of Exclusive License: The use of cyanovirin-N in a Topical Microbicide To Prevent the Transmission of HIV and Other Sexually Transmitted Diseases Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 2, 2001 will be considered.
View Prospective Grant of Exclusive License: The ex vivo use of cyanovirin-N To Remove or Inactivate HIV in Fluid Samples Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 2, 2001 will be considered.
View Prospective Grant of Exclusive License: The Systemic in vivo use of cyanovirin-N as a Prophylactic or Therapeutic Against HIV and Enveloped Viruses that Cause Hemorrhagic Fever Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 2, 2001 will be considered.
View Prospective Grant of Exclusive License: Identification of TRP-2 as a New Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes Only written comments and/or license applications which are received by the National Institutes of Health on or before June 4, 2001 will be considered.
View Prospective Grant of Exclusive License: The Use of Recombinant Cholera Toxin B Subunit to Treat Autoimmune and/or Inflammatory Diseases Only written comments and/or license applications which are received by the National Institutes of Health on or before May 22, 2001 will be considered.
View Prospective Grant of Co-Exclusive License: Treating Inflammatory Bowel Disease Using Antibodies Against Interleukin-Twelve (IL-12) Only written comments and/or license applications which are received by the National Institutes of Health on or before May 22, 2001 will be considered.
View National Institutes of Health, National Institute on Child Health and Human Development; Opportunity for Cooperative Research and Development Agreement Interested parties should notify this office in writing of their intent to file a formal proposal no later than April 13, 2001. Formal proposals must be submitted to this office no later than May 14, 2001.
View Government-Owned Inventions; Availability for Licensing
View National Cancer Institute (NCI) Collaborative Development of Methods for Selective T Cell Depletion To Improve Bone Marrow Transplantation Procedures
View National Institute on Child Health and Human Development (NICHD); Opportunity for Cooperative Research and Development Agreement Interested parties should notify this office in writing of their intent to file a formal proposal no later than April 11, 2001. Formal proposals must be submitted to this office no later than May 11, 2001.
View Centers for Disease Control and Prevention
View Prospective Grant of Co-Exclusive License: Homogeneous Tests for Sequentially Determining Lipoprotein Fractions Only written comments and/or applications for a license which are received by he NIH Office of Technology Transfer on or before April 27, 2001 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Method and Apparatus for Constructing Tissue Microarrays Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 23, 2001 will be considered.
View National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Opportunity for Cooperative Research and Development Agreements (CRADAs) to Develop Monoclonal Antibodies and/or Other Reagents and Products for Use in Identifying the Dombrock Blood Group Carrier Molecule Aimed at Improving Blood Typing Practices Through Molecular Means Only written CRADA capability statements received by the NIDDK on or before March 30, 2001 will be considered during the initial design phase; confidential information must be clearly labeled. Potential Collaborators may be invited to meet with the Selection Committee at the Collaborator's expense to provide additional information. The Institute may issue an additional notice of CRADA opportunity during the design phase.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Orally Active Derivatives of 1,3,5(10)-Estratriene Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before March 19, 2001 will be considered.
View Prospective Grant of Exclusive License: Prophylactic and/or Therapeutic Vaccine Against Pseudomonas Aeruginosa, Chlamydia, Trachomatis and Mycoplasma Pneumonia Only written comments and/or applications for a license which are received by NIH on or before March 19, 2001 will be considered.
View Prospective Grant of Exclusive License: Method for Preparing 17α-Acetoxy-11β-(4-,N-Dimethylaminophyl)-19-Norpregna-4, 9-Diene-3,20-Dione, Intermediates Useful in the Method, and Methods for the Preparation of Such Intermediates Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before April 18, 2001 will be considered.
View National Cancer Institute; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Identification and Development of Chemical Compounds That Interact With the Polo-Box of Polo Kinases, as Potential Therapeutic Targets for the Inhibition of Cellular Proliferation Interested parties should notify this office in writing of their interest in filing a formal proposal on or before March 12, 2001. Potential CRADA Collaborators will then have until on or before April 11, 2001 to submit a formal proposal. CRADA proposals submitted thereafter may be considered if a suitable CRADA Collaborator has not been selected.
View Prospective Grant of Exclusive License: Hydroxylamine Compositions for the Prevention or Retardation of Cataracts Only written comments and/or application for a license which is received by the NIH Office of Technology Transfer on or before February 26, 2001, will be considered.
View Prospective Grant of Exclusive License: Treatment of Retroviral Infections With a Phorbol Ester Derivative Only written comments and/or license applications which are received by the NIH Office of Technology Transfer on or before February 20, 2001 will be considered.
View Prospective Grant of Exclusive License: Compositions and Methods for the Stimulation of Proliferation and Differentiation of Pancreatic Cells Ex Vivo Only written comments and/or applications for a license which are received by NIH on or before February 5, 2001, will be considered.